Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
By leveraging digital screening and remote consultation, the medical community is moving beyond the confines of the clinic
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
The standout story remains Wegovy, particularly its new oral formulation
The private funding rose 38% amid growing international collaborations and CDMO demand
Funds to support product expansion, quick commerce growth, and manufacturing scale-up for holistic period care solutions
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Subscribe To Our Newsletter & Stay Updated
